Figures last updated 21 Oct 2026, 11:00 PM IST · How we work · Report an error
What the company does and where it sits in its industry
Paras Healthcare Limited provides tertiary and quaternary healthcare services through a multi-specialty hospital platform operating across North India, Bihar, and Jharkhand.
Paras Healthcare Limited is a clinical specialty-led healthcare provider offering tertiary and quaternary healthcare services through a network of eight operational hospitals across North India, Bihar, and Jharkhand under the 'Paras Health' brand. As of June 30, 2026, the company operated 2,211 beds across facilities located in Gurugram and Panchkula (Haryana), Patna and Darbhanga (Bihar), Kanpur (Uttar Pradesh), Udaipur (Rajasthan), Ranchi (Jharkhand), and Srinagar (Jammu & Kashmir).
The company's clinical care is centered on core specialty clusters known as 'CONGOR'—cardiac sciences, oncology sciences, neuro sciences, gastro sciences, orthopedics and sports injury, and renal sciences. These clinical specialties accounted for 74.70% of revenue from operations in Fiscal 2026 and 74.35% in the three months ended June 30, 2026.
The company earns revenue primarily through healthcare services provided to inpatients and outpatients, sales of pharmaceutical products at its hospital-based pharmacies, and other operating activities. Its patient revenue base is diversified across self-pay patients, private insurance/third-party administrators (TPAs), and government-sponsored healthcare schemes and public sector undertakings (PSUs).
The company provides inpatient and outpatient healthcare services across super-specialty and tertiary clinical programs including cardiac, oncology, neuro, gastro, orthopedics, and renal sciences, along with in-house pharmacy and diagnostic services.
The company operates its hospitals through a combination of owned, long-term leased, revenue-sharing, and public-private partnership (PPP) models.
The company is one of the largest healthcare providers in North India, Bihar and Jharkhand in terms of bed capacity, with 2,211 beds across eight hospitals as of June 30, 2026.
Who controls the company, and how much of it they hold
Dr. Dharminder Kumar Nagar
Points to weigh, drawn from the offer document and the figures on the other tabs
The company is one of the largest healthcare providers in North India, Bihar, and Jharkhand with 2,211 beds across eight hospitals as of June 30, 2026, having established early presences in cities like Gurugram, Patna, and Srinagar.
The company's clinical model emphasizes high-acuity treatments across cardiac, oncology, neuro, gastro, orthopedics, and renal specialties, which accounted for 74.70% of revenue from operations in Fiscal 2026.
Hospitals are operated through a mix of owned, leased, revenue-sharing, and public-private partnership models, enabling lower upfront capital intensity and disciplined expansion.
Clinical care is anchored by a team of experienced doctors, including three Padma Shri awardees, supported by advanced technologies such as LINACs, PET-CT scanners, and robotic surgical systems.
The company is led by a clinician-promoter with over 22 years of experience in the sector, supported by seasoned management professionals across operational, financial, and clinical disciplines.
The company incurred consolidated net losses of ₹153.31 million in Fiscal 2024, ₹579.83 million in Fiscal 2025, and ₹10.24 million in the three months ended June 30, 2025, primarily due to the ramp-up of new hospitals and capacity expansion.
Five of the company's eight hospitals are located in North India, contributing 66.07% of consolidated revenue from operations in Fiscal 2026, making it susceptible to regional economic and operational disruptions.
The business relies heavily on skilled doctors and nurses, having experienced overall employee attrition rates of 65.27% in Fiscal 2024, 66.74% in Fiscal 2025, and 60.38% in Fiscal 2026.
Six of eight hospitals operate on leased premises, with lease deeds for Panchkula, Darbhanga, Srinagar, and Ranchi hospitals being unregistered, which may affect their evidentiary value and legal enforceability.
The company had outstanding fund-based borrowings of ₹9,394.67 million on a consolidated basis as of August 31, 2026, requiring substantial cash flows to service principal and interest obligations.